Methods for staining mitochondria are disclosed involving using a composition containing a cationic species of the formula: (I) wherein at least one of Y and Z is a substituted or unsubstituted azetidine group; X is selected from O, S, SO2, Se, NR12, P(O)R12, CR13R14, SiR13R14, Te, and GeR13R14. Also disclosed are methods for analysing mitochondria, involving staining a sample of mitochondria. illuminating the stained sample using light of an appropriate wavelength to fluoresce the compound, and observing or imaging a magnified image of the sample.
Methods for staining mitochondria are disclosed involving using a composition containing a cationic species of the formula: (I) wherein at least one of Y and Z is a substituted or unsubstituted azetidine group; X is selected from O, S, SO2, Se, NR12, P(O)R12, CR13R14, SiR13R14, Te, and GeR13R14. Also disclosed are methods for analysing mitochondria, involving staining a sample of mitochondria. illuminating the stained sample using light of an appropriate wavelength to fluoresce the compound, and observing or imaging a magnified image of the sample.
Azetidine substitute rosamines useful for staining mitochondria of formula (I) are disclosed, wherein at least one of Y and Z is a substituted or unsubstituted azetidine group; X is selected from O, S, SO2, Se, NR12, P(O)R12, CR13R14, SiR13R14, Te, and GeR13R14, and there is at least one Q group on the pendant phenyl, the Q group comprising a group selected from halo, maleimidyl, OSO2R13 and epoxide. Also disclosed are methods for staining mitochondria involving incubating a sample in a composition comprising the compound, and analysing mitochondria, involving staining a sample of mitochondria, optionally fixing the cells, illuminating the stained sample using light of an appropriate wavelength to fluoresce the compound, and observing or imaging a magnified image of the sample.
Azetidine substitute rosamines useful for staining mitochondria of formula (I) are disclosed, wherein at least one of Y and Z is a substituted or unsubstituted azetidine group; X is selected from O, S, SO2, Se, NR12, P(O)R12, CR13R14, SiR13R14, Te, and GeR13R14, and there is at least one Q group on the pendant phenyl, the Q group comprising a group selected from halo, maleimidyl, OSO2R13 and epoxide. Also disclosed are methods for staining mitochondria involving incubating a sample in a composition comprising the compound, and analysing mitochondria, involving staining a sample of mitochondria, optionally fixing the cells, illuminating the stained sample using light of an appropriate wavelength to fluoresce the compound, and observing or imaging a magnified image of the sample.
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07F 7/08 - Compounds having one or more C—Si linkages
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
HELMHOLTZ ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBH (Germany)
UNIVERSITÄT ZU LÜBECK (Germany)
Inventor
Maple, Hannah
Marsh, Graham
Moloney, Alex
Karadogan, Burhan
Brönstrup, Mark
Siemon, Thomas
Rox, Katharina
Hilgenfeld, Rolf
Abstract
PL2LL comprises an E3 ubiquitin ligase ligand. Also disclosed are pharmaceutical compositions comprising such compounds or combinations, and methods and reagents using the compounds. Compounds may have therapeutic uses and uses in research.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
HELMHOLTZ ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBH (Germany)
UNIVERSITÄT ZU LÜBECK (Germany)
Inventor
Maple, Hannah
Marsh, Graham
Moloney, Alex
Karadogan, Burhan
Brönstrup, Mark
Siemon, Thomas
Rox, Katharina
Hilgenfeld, Rolf
Abstract
L21LL comprises an E3 ubiquitin ligase ligand. Also disclosed are pharmaceutical compositions comprising such compounds or combinations, and methods and reagents using the compounds. Compounds may have therapeutic uses and uses in research.
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
2121213141314131421313 and epoxide. Also disclosed are methods for staining mitochondria involving incubating a sample in a composition comprising the compound, and analysing mitochondria, involving staining a sample of mitochondria, optionally fixing the cells, illuminating the stained sample using light of an appropriate wavelength to fluoresce the compound, and observing or imaging a magnified image of the sample.
2121213141314131414. Also disclosed are methods for analysing mitochondria, involving staining a sample of mitochondria, illuminating the stained sample using light of an appropriate wavelength to fluoresce the compound, and observing or imaging a magnified image of the sample.
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
01 - Chemical and biological materials for industrial, scientific and agricultural use
42 - Scientific, technological and industrial services, research and design
Goods & Services
Chemicals; radiochemicals; radioligands; neurochemicals;
signal transduction agents; peptides; biochemicals;
pharmacological probes and categorised collections of
chemicals. Scientific and technological services; scientific,
consultancy and research services; chemistry services;
chemical laboratory services; scientific, technological,
research and design services relating to chemicals;
preparation of reports relating to chemistry and chemicals;
analysis and testing of chemicals; advice and support
services relating to the foregoing.
